Toric IOLs good choice to correct astigmatism

Article

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism.

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism, said Jorge Alio, MD at the Acri.Tec symposium.

"Cataract surgery should not induce or change pre-existing astigmatism. It needs to be controlled, stable and precise and correction should not induce other optical changes, such as increased aberrations as this will cause a shift in the spherical correction of the eye," said Dr Alio.

Toric IOLs are a good choice because they offer full correction of the whole refractive error, and may correct for an unlimited amount of astigmatism.

Dr Alio outlined one cataract patient with preoperative UCVA counting fingers at 2 metres, with refraction of -4.5 sphere -6.5 and cylinder of 10. The patient underwent microincision cataract surgery (MICS) with Acri.Tec's Acri.Comfort 646 TLC implantation. The power was refraction +15.5, sphere +6.5 and cylinder of 100, achieving postoperative goal refraction of -0.27 sphere and -0.11 cylinder.

"Immediately, in the first postoperative day, the patient achieved 0.2 UCVA," said Dr Alio. "At three months postoperatively the patient had a UCVA 0.4, BCVA 0.5 with a refraction of 1, sphere -1 and cylinder 130," enthused Dr Alio.

The Acri.Comfort 646 is the only commercially available Toric MICS IOL, and it offers an unlimited amount of astigmatic correction during cataract surgery, according to Dr Alio. "Its rotational stability is excellent, and it gives outstanding refractive outcomes. It is the Toric pseudophakic IOL of choice in our clinic," he concluded.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.